96 related articles for article (PubMed ID: 28373427)
21. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.
Singh PP; Joshi S; Russell PJ; Verma ND; Wang X; Khatri A
Clin Cancer Res; 2011 Jun; 17(12):4006-18. PubMed ID: 21531822
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
Hung H
Mol Cancer Ther; 2007 Aug; 6(8):2149-57. PubMed ID: 17699714
[TBL] [Abstract][Full Text] [Related]
23. Comparative chemosensitivity of circulating human prostate cancer cells and primary cancer cells.
Menen R; Zhao M; Zhang L; Hassanein MK; Bobek V; Kolostova K; Bouvet M; Hoffman RM
Anticancer Res; 2012 Jul; 32(7):2881-4. PubMed ID: 22753751
[TBL] [Abstract][Full Text] [Related]
24. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
[TBL] [Abstract][Full Text] [Related]
25. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
26. Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.
Wenner CA; Martzen MR; Lu H; Verneris MR; Wang H; Slaton JW
Int J Oncol; 2012 Apr; 40(4):905-13. PubMed ID: 22159900
[TBL] [Abstract][Full Text] [Related]
27. Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model.
Choi ES; Jung JY; Lee JS; Park JH; Cho NP; Cho SD
Cancer Lett; 2013 Jan; 328(1):65-72. PubMed ID: 23000424
[TBL] [Abstract][Full Text] [Related]
28. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice.
Church D; Zhang Y; Rago R; Wilding G
Cancer Chemother Pharmacol; 1999; 43(3):198-204. PubMed ID: 9923549
[TBL] [Abstract][Full Text] [Related]
30. Effective photothermal chemotherapy with docetaxel-loaded gold nanospheres in advanced prostate cancer.
Shen Y; Ma Z; Chen F; Dong Q; Hu Q; Bai L; Chen J
J Drug Target; 2015; 23(6):568-76. PubMed ID: 25738990
[TBL] [Abstract][Full Text] [Related]
31. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
32. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.
Bandyopadhyay A; Wang L; López-Casillas F; Mendoza V; Yeh IT; Sun L
Prostate; 2005 Apr; 63(1):81-90. PubMed ID: 15468171
[TBL] [Abstract][Full Text] [Related]
33. A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment.
Rayan M; Shadafny S; Falah A; Falah M; Abu-Lafi S; Asli S; Rayan A
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164226
[TBL] [Abstract][Full Text] [Related]
34. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
[TBL] [Abstract][Full Text] [Related]
35. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
[TBL] [Abstract][Full Text] [Related]
36. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels.
Tang Y; Parmakhtiar B; Simoneau AR; Xie J; Fruehauf J; Lilly M; Zi X
Neoplasia; 2011 Feb; 13(2):108-19. PubMed ID: 21403837
[TBL] [Abstract][Full Text] [Related]
37. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer.
Darnowski JW; Goulette FA; Cousens LP; Chatterjee D; Calabresi P
Cancer Chemother Pharmacol; 2004 Sep; 54(3):249-58. PubMed ID: 15173956
[TBL] [Abstract][Full Text] [Related]
38. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
[TBL] [Abstract][Full Text] [Related]
39. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
[TBL] [Abstract][Full Text] [Related]
40. Suppressed tumour growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model.
Kumano M; Miyake H; Terakawa T; Furukawa J; Fujisawa M
BJU Int; 2010 Jul; 106(1):121-7. PubMed ID: 19912186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
